NK

Naveen Krishnan

Physician/Operator/Investor

Boston, Massachusetts

Invests in

Sectors:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Board Member

    2023

  • SVP & Managing Director

    2023

    Leading Mirae Asset Financial Group's ($600bn AUM) first U.S.-based venture capital firm dedicated to investing in life science companies

2020 - 2023

  • Senior Director of Venture Investment

    2020 - 2023

    Helped to lead minority equity investments in healthcare across genetic disease/gene therapy, cell therapy, regenerative medicine, oncology, autoimmune disease/inflammation, CNS/mental health, and digital health

2022 - 2023

  • Board Member

    2022 - 2023

    Deep understanding of protein homeostasis and ubiquitin biology to effect protein modulation (e.g. degradation) beginning in CNS.

2021 - 2023

  • Board Member

    2021 - 2023

    Leveraging the gut-brain-immune axis to deliver live biotherapeutic products in CNS indications (Epilepsy, ALS)

2021 - 2023

  • Board Member

    2021 - 2023

    AI-driven chat bot utilizing validated psychiatry/psychology principles (CBT, DBT, IPT) to deliver prescription and non-prescription digital therapeutics for mental health.

2021 - 2023

  • Board Member

    2021 - 2023

    One of the world's leading health symptom assessment apps revolutionizing the digital healthcare journey for patients.

2021 - 2022

  • Board Member

    2021 - 2022

    Revolutionizing the manufacturing for iPSC-derived cell therapies

2021 - 2022

  • Board Member

    2021 - 2022

    Developing the first biomarker for systemic chronic inflammation using serum-derived immunological proteins leveraging the data from a 10-year longitudinal study from Stanford (1KIP).

2021 - 2022

  • Board Member

    2021 - 2022

    Genetic engineering of skin microbes to treat dermatologic conditions with a lead program in Netherton Syndrome. IND for Netherton syndrome cleared by FDA at the end of 2022, IPO in H1 2023 (NYSE: AZTR).